Company news
ALX Oncology Holdings Inc. news in 2020
ALX Oncology Holdings Inc.'s news releases, calls and decks from 2020, newest first.
ALX Oncology Announces Closing of Public Offering and Full Exercise of the Underwriters’ Option to Purchase Additional Shares
December 13, 2020
ALX Oncology Announces Pricing of Upsized Public Offering of Common Stock
December 8, 2020
ALX Oncology Announces Updates on Planned ALX148 Phase 2 Head and Neck Cancer Studies
December 6, 2020
ALX Oncology Announces Updated Data from ASPEN-01, the Ongoing Phase 1b Study of ALX148, Showing Robust, Durable Activity in Patients with Non-Hodgkin Lymphoma
December 6, 2020
ALX Oncology Announces Proposed Public Offering of Common Stock
December 6, 2020
ALX Oncology Reports Third Quarter 2020 Financial Results and Provides Clinical Development and Operational Highlights
November 11, 2020
ALX Oncology Announces New Data from ASPEN-01, the Phase 1b Study of ALX148, Showing Promising Initial Clinical Responses in Patients with Advanced Solid Tumors
November 8, 2020
ALX Oncology Announces First Patient Dosed in ASPEN-02, a Phase 1/2 Study of ALX148 in Combination with Azacitidine in Patients with Myelodysplastic Syndrome
October 27, 2020
ALX Oncology Names Leading Oncology Experts to Scientific Advisory Board
October 5, 2020
ALX Oncology to Collaborate with Merck on Phase 2 Immuno-Oncology Studies Evaluating ALX148, Targeting CD47, in Combination with KEYTRUDA® (pembrolizumab) in Patients with Head & Neck Cancer
September 21, 2020
ALX Oncology Reports Second Quarter 2020 Financial Results and Provides Operational and Clinical Highlights
August 26, 2020
ALX Oncology Announces Closing of Initial Public Offering and Full Exercise of the Underwriters’ Option to Purchase Additional Shares
July 20, 2020
ALX Oncology Announces Pricing of Initial Public Offering
July 15, 2020